Chargement en cours...
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB(4) receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis
BACKGROUND: Airway inflammation, mediated in part by LTB(4), contributes to lung destruction in patients with cystic fibrosis (CF). LTB(4)-receptor inhibition may reduce airway inflammation. We report the results of a randomized, double-blind, placebo-controlled study of the efficacy and safety of t...
Enregistré dans:
| Publié dans: | J Cyst Fibros |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4755340/ https://ncbi.nlm.nih.gov/pubmed/24440167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2013.12.009 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|